The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis

被引:61
|
作者
Eng, Simon W. M. [1 ,2 ]
Duong, Trang T. [1 ]
Rosenberg, Alan M. [3 ]
Morris, Quaid [2 ]
Yeung, Rae S. M. [1 ,2 ]
机构
[1] Hosp Sick Children, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Saskatchewan, Saskatoon, SK, Canada
基金
加拿大健康研究院;
关键词
PRIMARY SJOGRENS-SYNDROME; HUMAN MONOCLONAL-ANTIBODIES; MEMORY B-CELLS; CLASSIFICATION CRITERIA; SALIVARY-GLANDS; PERIPHERAL-BLOOD; ANTI-RO/SSA; AUTOANTIBODIES; REPERTOIRE;
D O I
10.1002/art.38875
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Childhood arthritis encompasses a heterogeneous family of diseases. Significant variation in clinical presentation remains despite consensusdriven diagnostic classifications. Developments in data analysis provide powerful tools for interrogating large heterogeneous data sets. We report a novel approach to integrating biologic and clinical data toward a new classification for childhood arthritis, using computational biology for data-driven pattern recognition. Methods. Probabilistic principal components analysis was used to transform a large set of data into 4 interpretable indicators or composite variables on which patients were grouped by cluster analysis. Sensitivity analysis was conducted to determine key variables in determining indicators and cluster assignment. Results were validated against an independent validation cohort. Results. Meaningful biologic and clinical charac-teristics, including levels of proinflammatory cytokines and measures of disease activity, defined axes/indicators that identified homogeneous patient subgroups by cluster analysis. The new patient classifications resolved major differences between patient subpopulations better than International League of Associations for Rheumatology subtypes. Fourteen variables were identified by sensitivity analysis to crucially determine indicators and clusters. This new schema was conserved in an independent validation cohort. Conclusion. Data-driven unsupervised machine learning is a powerful approach for interrogating clinical and biologic data toward disease classification, providing insight into the biology underlying clinical heterogeneity in childhood arthritis. Our analytical framework enabled the recovery of unique patterns from small cohorts and addresses a major challenge, patient numbers, in studying rare diseases.
引用
收藏
页码:3463 / 3475
页数:13
相关论文
共 50 条
  • [1] Biologic agents in Juvenile Idiopathic Arthritis
    Gomes, J. A. Melo
    [J]. ACTA REUMATOLOGICA PORTUGUESA, 2007, 32 (01): : 13 - 14
  • [2] Biologic Therapies in Juvenile Idiopathic Arthritis
    Tanatar, Ayse
    Ayaz, Nuray Aktay
    [J]. MEDICAL JOURNAL OF BAKIRKOY, 2023, 19 (03) : 269 - 275
  • [3] Biologic therapies in systemic juvenile idiopathic arthritis
    Batu, Ezgi Deniz
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (06): : 621 - 629
  • [4] Response to biologic treatment in juvenile idiopathic arthritis
    Lapraik, C. J.
    Barrows, P.
    Somerville, M.
    Armon, K.
    Tranter, C.
    Scott, D. G. I.
    [J]. RHEUMATOLOGY, 2006, 45 : I116 - I116
  • [5] Treatment of Juvenile Idiopathic Arthritis in the Biologic Age
    Stoll, Matthew L.
    Cron, Randy Q.
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2013, 39 (04) : 751 - +
  • [6] Outcome in Juvenile Idiopathic Arthritis (JIA). Earlier biologic drugs treatment could be effective in preventing clinical and radiological progression of juvenile idiopathic arthritis
    Spinelli, Alessandro M.
    Taddio, Andrea
    Lepore, Loredana
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 419 - 420
  • [7] The safety profile of biologic therapies for juvenile idiopathic arthritis
    Philip J. Hashkes
    Yosef Uziel
    Ronald M. Laxer
    [J]. Nature Reviews Rheumatology, 2010, 6 : 561 - 571
  • [8] Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
    Juan Carlos Nieto-González
    Laura Trives-Folguera
    Alejandra Melgarejo-Ortuño
    Aranzazu Ais
    Belén Serrano-Benavente
    María Sanjurjo
    José María Álvaro-Gracia
    Indalecio Monteagudo Sáez
    [J]. Scientific Reports, 11
  • [9] USE OF BIOLOGIC AGENTS IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS
    McErlane, Flora
    Kulkarni, Priyanka
    Nicholl, Karl
    Foster, Helen E.
    [J]. RHEUMATOLOGY, 2010, 49 : I88 - I88
  • [10] The safety profile of biologic therapies for juvenile idiopathic arthritis
    Hashkes, Philip J.
    Uziel, Yosef
    Laxer, Ronald M.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (10) : 561 - 571